Navigation Links
BioMed Realty Trust Completes South San Francisco Portfolio Acquisition
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced that it has completed the previously announced acquisition of the Science Center at Oyster Point and the Gateway Business Park, two adjacent life science campuses in the South San Francisco life science market, comprised of a total of approximately 489,000 square feet of laboratory, office and industrial space. The properties were purchased for approximately $298 million.

(Logo:  http://photos.prnewswire.com/prnh/20091005/BIOMEDLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO)

The Science Center at Oyster Point is comprised of two newly constructed, state-of-the-art research facilities with an aggregate of approximately 205,000 square feet of space, which are 100% leased on a long-term basis to Elan Corporation. The Gateway Business Park, a research and development park with an aggregate of approximately 284,000 square feet, is fully leased to Elan, FedEx Corporation and Genentech, Inc., a member of the Roche Group.  As part of the acquisition, the company assumed a development agreement with the city of South San Francisco that would permit redevelopment of the campus to a total of approximately 1.23 million square feet of rentable space, representing a net increase of approximately 946,000 square feet.

Kent Griffin, President and Chief Operating Officer of BioMed, remarked, "We are very excited about this significant enhancement to BioMed's footprint in the South San Francisco submarket and our overall platform in the San Francisco Bay area. These properties exemplify BioMed's successful business model of investing in the highest quality, well-located, state-of-the-art research facilities wit
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
2. Regenesis Biomedical Announces Additions to Board of Directors
3. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
4. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
5. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
6. BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
7. BioMed Realty Trust Announces Exercise of Over-Allotment Option
8. Isilon CTO Addresses Life Science Data Storage Challenges at Harvard Medical Schools BioMedical HPC Leadership Summit
9. BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk
10. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
11. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in ... for the treatment of Alzheimer,s and other neurological ... collaboration agreement with the University California, Irvine to ... vaccine candidate to induce an immune response against ...
... Conference: May 21-24, 2012 ,Exhibition: May 22-24, 2012 ,Pennsylvania ... Medical Design and Manufacturing (MD&M) East Conference have announced ... Convention Center, May 21 - 24, 2012. The conference ... dedicated to medical design and manufacturing professionals, featuring presentations ...
... CMC Biologics is a leading contract manufacturing organization (CMO) ... process development and cGMP manufacture of ... growth factors), as well as monoclonal antibodies. CMC ... characterization capabilities, expertise in continuous perfusion systems and ...
Cached Biology Technology:Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 2Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 3Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 4MD&M East 2012 to Feature FDA and Medical Technology Development Leaders 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 3CMC Biologics Highlights Technical Acumen at Upcoming Conferences 4CMC Biologics Highlights Technical Acumen at Upcoming Conferences 5
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... PITTSBURGH Nov. 9, 2007 Researchers at Childrens Hospital ... trial currently underway to study the effectiveness of oral insulin ... in people at risk for the disease. The researchers ... prevent or delay the onset of type 1 diabetes in ...
... will convene at the Institute of Ecosystem Studies ... future of biofuel production in the United States. ... biofuel experts, including Drs. David Pimentel (Cornell University), ... State)., Corn and soy-based ethanol have been touted ...
... barbecue knows that hot dogs are inexplicably packaged in different ... 10 hot dog buns. Put in ecological terms, this means ... are worthless without hot dogs to fill them. ... phosphorus or nitrogen limits plant production in most ecosystems. According ...
Cached Biology News:Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2Can plant-based ethanol save us from our fossil fuel addiction? 2At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: